Inhibitex Regains Compliance with NASDAQ Listing Requirements
February 05 2010 - 3:30PM
Business Wire
Inhibitex, Inc. (Nasdaq: INHX) (the “Company”), a
biopharmaceutical company focused on developing products to treat
serious infectious diseases, announced today that it has received
notice from The NASDAQ Stock Market ("Nasdaq") stating that, as the
bid price of the Company’s common stock has closed at or above
$1.00 per share for 10 consecutive business days, the Company has
regained compliance with Nasdaq’s Listing Rule 5550(a)(2) and its
delisting matter has been closed. Accordingly, the Company is
currently in full compliance with all listing requirements of the
Nasdaq Capital Market.
For additional information about the
Company, please visit www.inhibitex.com.
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jul 2023 to Jul 2024